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ABSTRACT
Objective To identify genetic causes of COACH
syndrome
Background COACH syndrome is a rare autosomal
recessive disorder characterised by Cerebellar vermis
hypoplasia, Oligophrenia (developmental delay/mental
retardation), Ataxia, Coloboma, and Hepatic fibrosis. The
vermis hypoplasia falls in a spectrum of mid-hindbrain
malformation called the molar tooth sign (MTS), making
COACH a Joubert syndrome related disorder (JSRD).
Methods In a cohort of 251 families with JSRD, 26
subjects in 23 families met criteria for COACH syndrome,
defined as JSRD plus clinically apparent liver disease.
Diagnostic criteria for JSRD were clinical findings
(intellectual impairment, hypotonia, ataxia) plus
supportive brain imaging findings (MTS or cerebellar
vermis hypoplasia).MKS3/TMEM67 was sequenced in all
subjects for whom DNA was available. In COACH
subjects without MKS3 mutations, CC2D2A, RPGRIP1L
and CEP290 were also sequenced.
Results 19/23 families (83%) with COACH syndrome
carried MKS3 mutations, compared to 2/209 (1%) with
JSRD but no liver disease. Two other families with
COACH carried CC2D2A mutations, one family carried
RPGRIP1L mutations, and one lacked mutations in MKS3,
CC2D2A, RPGRIP1L and CEP290. Liver biopsies from
three subjects, each with mutations in one of the three
genes, revealed changes within the congenital hepatic
fibrosis/ductal plate malformation spectrum. In JSRD with
and without liver disease, MKS3 mutations account for
21/232 families (9%).
Conclusions Mutations in MKS3 are responsible for the
majority of COACH syndrome, with minor contributions
from CC2D2A and RPGRIP1L; therefore, MKS3 should be
the first gene tested in patients with JSRD plus liver
disease and/or coloboma, followed by CC2D2A and
RPGRIP1L.
COACH syndrome (MIM 216360) was proposed in
1989 by Verloes and Lambotte to describe the
combination of Cerebellar vermis hypoplasia
(CVH), Oligophrenia (developmental delay/mental
retardation), Ataxia, Colobomas, and Hepatic
fibrosis in three individuals including two siblings.1
Since that initial description, more than 40 indi-
viduals have been described with that constellation
of findings or a subset thereof. In 1999, Satran et al2
proposed that COACH syndrome represents
a subtype of the autosomal recessive disorder
Joubert syndrome (MIM 213300) manifesting liver
disease. In 2004, Gleeson et al3 established that the
CVH in COACH syndrome was accompanied by
elongation of the superior cerebellar peduncles and
a deep interpeduncular fossa on brain magnetic
resonance imaging (MRI), all features that consti-
tute the molar tooth sign (MTS), the key feature of
Joubert syndrome and related disorders (JSRD). As
a JSRD subtype, COACH syndrome manifests core
neurological features including the MTS, hypotonia
in infancy with later development of ataxia, devel-
opmental delay/mental retardation, abnormal
breathing pattern (tachypnoea and/or apnoea) and
abnormal eye movements (typically, nystagmus,
oculomotor apraxia (OMA) or difficulty with
smooth visual pursuit).4e6 Other features variably
reported in JSRD include dysmorphic facial features,
polydactyly, retinal dystrophy, chorioretinal colo-
bomas, renal disease (cysts or juvenile neph-
ronophthisis), hepatic fibrosis, and tongue papules
or oral frenulae.7e9
The autosomal recessive disorder Meckel
(Gruber) syndrome (MKS; MIM 607361) typically
manifests prenatal or perinatal lethality and is
characterised by the triad of posterior fossa brain
malformation (90% occipital encephalocele), cystic
renal dysplasia, and congenital liver disease (the
ductal plate malformation (DPM)).10e13 These
features place MKS within a wider group of
congenital hepato-renal fibrocystic diseases that
include autosomal recessive polycystic kidney
disease (ARPKD), nephronophthisis with liver
fibrosis, BardeteBiedl syndrome and Jeune asphyx-
iating thoracic dystrophy. The DPM (figure 1A) is
thought to result from incomplete remodelling of
the embryonic ductal plate which normally leads to
the mature structure of the portal triad (figure 1B).
This developmental arrest is associated with the
presence of an excess of dilated bile ducts, often
arranged in a circular profile, as well as portal
fibrosis. It is often referred to as congenital hepatic
fibrosis (CHF), especially after infancy when the
ducts typically become less conspicuous and dense
fibrosis predominates.14e16
Marked genetic heterogeneity exists for JSRD
and MKS. Mutations in seven genes (NPHP1,
AHI1, CEP290, RPGRIP1L, MKS3/TMEM67,
CC2D2A and ARL13B) and two additional loci
(9q34, pericentromeric chromosome 11) have been
1University of Washington,
Seattle, Washington, USA
2National Institutes of Health,
Bethesda, Maryland, USA
3University of Washington,
Seattle, Washington, USA
4Mary Bridge Pediatric
Neurology, Tacoma,
Washington, USA 5University of
New Mexico Health Sciences
Center, Albuquerque, New
Mexico, USA 6Hacettepe
University, Ankara, Turkey
7University of Groningen,
Groningen, The Netherlands
8IRCCS de Bellis Hospital,
Castellana Grotte, Italy 9Ondokuz
Mayis University, Samsun,
Turkey 10University of California,
San Francisco, San Francisco,
California, USA 11Hopital Robert
DEBRE, Paris, France
12University of Munich, Munich,
Germany 13University of
Chicago, Chicago, Illinois, USA
Correspondence to
Dr D Doherty, University of
Washington Box 356320, 1959
NE Pacific St, Seattle, WA
98195-0320, USA;
ddoher@u.washington.edu
DD and MAP contributed equally
Received 19 February 2009
Revised 12 May 2009
Accepted 15 May 2009
Published Online First
1 July 2009
8 J Med Genet 2010;47:8e21. doi:10.1136/jmg.2009.067249
Original article
 group.bmj.com on January 21, 2014 - Published by jmg.bmj.comDownloaded from 
associated with JSRD,17e30 but these account for only approxi-
mately 50% of patients. MKS1 and MKS3 are each estimated to
contribute to a variable percentage of total MKS patients, highly
dependent on ethnic background.31e34 Several of the genes
responsible for JSRD (CEP290, RPGRIP1L, MKS3/TMEM67,
CC2D2A) also cause MKS.20 22 35e38 This overlap is not comple-
tely unexpected given that the genes responsible for JSRD and
MKS are implicated in primary cilium/basal body function, and
both physical and genetic interactions between these proteins/
genes have been demonstrated.38 Given the shared genetic causes
of MKS and JSRD, the underlying pathophysiology of liver
disease in COACH syndrome is likely to lie within the same
spectrum as MKS.
Recently, Brancati et al39 identified MKS3 mutations in more
than half of probands with COACH syndrome, defined as JSRD
with CHF; however, the contribution of MKS3 mutations to
JSRD as a whole was not reported. In this work, we demon-
strate that MKS3 mutations account for 9% of families in
a large JSRD cohort, and that MKS3 mutations occur almost
exclusively in the JSRD plus clinically apparent liver disease
(COACH) subtype. In addition, we found RPGRIP1L and
CC2D2A mutations in families with COACH, and collectively,
Figure 1 Liver biopsy findings in
patients with COACH syndrome. (A)
Ductal plate malformation, fetus with
MKS: the portal triad with ductal plate
malformation has a ring of irregularly
shaped and dilated bile duct structures
that parallel the limiting plate. Trichrome,
1503. (B) Normal liver, 4 years: the
portal triad contains a bile duct (lower
left lumen), hepatic artery (lower right
lumen) and portal vein (upper lumen)
within a minimal amount of supporting
fibrocollagen. Trichrome, 3003. (C)
UW65, 11 months: the portal triad is
expanded by minimal fibrosis and too
many duct profiles, located both at the
limiting plate and within the connective
tissue. Trichrome, 2003. (D) UW65, 9
years: the portal triad has moderate
fibrosis and an excess of bile ducts and
hepatic artery branches with only
minimal inflammation. Trichrome, 2003.
(E) UW49, 10 years: the explanted liver
has dense portal fibrosis that extends
between triads and focally forms
nodules. Trichrome, 203. (F) UW49, 10
years: a portal triad in the explant shows
moderate fibrosis and several irregular
bile duct profiles. Trichrome, 3003. (G)
UW04-3, 5 years: the liver biopsy has
intact lobular architecture with portal
fibrosis and occasional septa bridging
portal areas. Trichrome, 203. (H)
UW04-3, 5 years: a representative portal
area shows several profiles of bile ducts
and hepatic artery branches within
dense fibrocollagen; central clear lumen
is a normal portal vein branch.
Trichrome, 3003.
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these three genes account for up to 96% of families with COACH
in our cohort.
SUBJECTS AND METHODS
Subjects
In cooperation with the Joubert Syndrome Foundation &
Related Cerebellar Disorders and clinical collaborators
throughout the world, the University of Washington (UW)
Joubert Center has enrolled >250 families with JSRD under an
approved protocol through the Human Subjects Division at the
University of Washington. All subjects in the cohort have clinical
findings of Joubert syndrome (intellectual impairment, hypo-
tonia, ataxia) and supportive brain imaging findings (MTS on
MRI or cerebellar vermis hypoplasia on computed tomography
(CT) scan). For subjects without brain MRI studies, vermis
hypoplasia was considered a sufficient imaging criterion. Diag-
nosis of CHF was based on medical record review using any one
of the following criteria: histopathological evidence of hepatic
fibrosis from either biopsy or autopsy, hepatic ultrasound/MRI
imaging findings consistent with fibrosis or bile duct dilatation,
otherwise unexplained elevated serum transaminases, hepato-
megaly, portal hypertension, portosystemic shunting, or liver
transplantation. Patients with an alternative cause for liver
disease (medication, infection, inflammation) were excluded.
Other features including coloboma, retinal disease, renal disease,
polydactyly, and encephalocele were identified based on parent/
physician report or medical record review. Ocular coloboma was
not required for the COACH diagnosis. Renal disease was
collated and assigned to the following categories using clinical,
imaging and histopathological data, as available: (1) neph-
ronophthisis, or (2) macrocystic renal disease, or (3) other renal
disease as reported. These criteria were also applied to interpre-
tation of historical reports of COACH syndrome.
Mutation identification
The known JSRD and MKS loci were excluded using micro-
satellite and single nucleotide polymorphism (SNP) genotyping
as previously described.38 The remaining probands were
sequenced for MKS3,37 40 CC2D2A,41 and RPGRIP1L19 as previ-
ously described. Sequencing of forward and reverse strands of all
exons plus 30e50 bp of flanking intronic sequence was
performed using BigDye v3.1 (Applied Biosystems, Foster City,
California, USA) terminator chemistry and reactions purified
with BigDye XTerminator (Applied Biosystems) technology.
Extension fragments were separated by capillary electrophoresis
on a 37303l DNA Analyzer (Applied Biosystems). Sequence
variants were identified using the software package, Variant
Reporter (Applied Biosystems). Confirmation of segregation of
mutations with disease status within a family was determined
for all mutations when parental and/or sibling DNA was avail-
able. Determination of the likelihood that missense mutations
would be deleterious was made using the PolyPhen program.42
NetGene2 (www.cbs.dtu.dk/services/NetGene2/), Genie (www.
fruitfly.org/seq_tools/splice.html), Human Splicing Finder
(www.umd.be/HSF/), SPL (linux1.softberry.com), and Splice-
View (http://zeus2.itb.cnr.it/ewebgene/wwwspliceview.html)
were used to model the effects of splice site mutations.43 44
Literature review
Review of all papers published in the medical literature with
reference to COACH syndrome was performed recording the age
of onset of hepatic disease, presenting signs/symptoms of liver
involvement, other associated features (MTS, colobomas in
particular), evidence of renal cystic disease, medical and/or
surgical interventions, and outcomes with regard to morbidity
and mortality associated with liver and/or kidney disease. In
some cases, direct contact with the authors yielded updated
clinical information. Patients without evidence of liver disease or
cerebellar vermis hypoplasia were excluded, as well as reports of
DekabaneArima syndrome, characterised by congenital amau-
rosis and polycystic kidneys.2 45 46
RESULTS
Patients with COACH syndrome due to mutations in MKS3,
CC2D2A or RPGRIP1L
Patient 1: MKS3/TMEM67
This 9-year-old male (UW65) was initially evaluated in his first
year of life for macrocephaly, overgrowth, hypotonia and
developmental delay (figure 2A). At 16 months, ophthalmologic
evaluation revealed rotatory nystagmus, OMA, reduced visual
acuity and bilateral inferior chorioretinal colobomas, sparing the
macula. A brain MRI demonstrated the MTS (figure 2BeC), and
Figure 2 Facial features, brain
imaging and mutations for UW65 and
UW49. (A) UW65 at 11 months of age.
(B and C) Sagittal T1 weighted and axial
T2 weighted brain magnetic resonance
images demonstrating the molar tooth
sign. (D) UW65 at 9 years of age. (E)
MKS3 sequence tracings for UW65. (F)
UW49 at 20 years of age. Photographs
printed with permission from the
families.
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he manifested developmental delay and an ataxic gait (walking
independently from 8 years of age). At 9 years, he uses two
words, follows complex commands, reads and types at a basic
level, and can do multiplication (figure 2D).
By 11 months of age, palpable hepatosplenomegaly with
fourfold elevated liver enzymes (aspartate transaminase (AST)
250 IU/l, alanine aminotransferase (ALT) 236 IU/l) prompted
liver biopsy which demonstrated minimal portal fibrosis and
excess of ductal elements (figure 1C). At age 6 years, he had
normal serum transaminases but “slightly coarsened” hepatic
echogenicity on abdominal ultrasound. At 9 years, mildly
elevated serum transaminases (AST 73 IU/l, ALT 92 IU/l) and
borderline splenomegaly prompted a second liver biopsy which
demonstrated progression of hepatic fibrosis with numerous duct
profiles in portal triads (figure 1D). Currently, his renal function
remains intact. Testing for the genes associated with JSRD
revealed compound novel missense mutations in theMKS3 gene
(figure 2E), with one mutation confirmed to be inherited from his
mother (paternal sample not available).
Patient 2: CC2D2A
This 22.5-year-old female (UW49), briefly reported in Gorden
et al (2008), has speech dyspraxia, reads at the 6th grade level, and
uses a wheelchair for mobility (figure 2F). She has moderate
intellectual disability (full scale IQ ¼ 41) and completed high
school in a regular classroom with a full time aide. She had
apnoea and tachypnoea as an infant, with episodic events
persisting into maturity. Ophthalmological evaluation revealed
OMA, strabismus, and bilateral small chorioretinal colobomas
inferior to the optic nerves. Cerebellar vermis hypoplasia, agen-
esis of the corpus callosum and hydrocephalus were identified on
head CT scans. Ventriculoperitoneal (VP) shunt, strabismus,
ptosis, bilateral inguinal hernia and tongue reduction surgeries
were required.
At 5.9 years of age, hepatosplenomegaly and elevated serum
transaminases led to a liver biopsy which showed portal fibrosis
and an excess of bile ducts. Progression of her liver disease led to
a second biopsy at 8.5 years of age, revealing mild-moderate
portal fibrosis with focal portaleportal bridging. By 10 years of
age, a transjugular intrahepatic portosystemic shunt was placed
for treatment of massive ascites and splenomegaly. Subsequently,
she received a paternal partial liver transplant for end stage liver
failure. The native liver showed moderate to severe dense portal
fibrosis with variably thick septa bridging portal regions and focal
nodule formation (figure 1E). Some portal triads contained an
excess of ducts, including a few irregularly complex forms (figure
1F). At 17 years, she developed mild chronic renal failure,
hypertension and renal tubular acidosis, medically treated.
Compound heterozygous mutations (one missense, one frame-
shift) were identified in the CC2D2A gene (table 1).38
Patient 3: RPGRIP1L
This 17.5-year-old male (UW04) presented at age 15 months
with hypotonia, developmental delay, alternating hyperpnoea/
apnoea and OMA. Brain MRI at 9 months of age demonstrated
the MTS. His younger brother had a very similar neonatal course
with milder OMA, plus unilateral ptosis, strabismus and autistic
behaviours. By the age of 5 years, he manifested ataxia and was
diagnosed with chronic anaemia and progressive renal insuffi-
ciency (blood urea nitrogen (BUN) 96 mg/dl and creatinine (Cr)
6.7 mg/dl). A renal ultrasound showed diffusely echogenic
kidneys of normal size. Combined renal and liver biopsies were
performed. The liver demonstrated mild to moderate portal
fibrosis with focal portaleportal bridging without inflammation
or cholestasis (figure 1G); many triads contained an excess
number of ducts (figure 1H). Neither biliary stasis nor an
inflammatory process was present. The renal biopsy showed
marked interstitial fibrosis and inflammation with tubular
atrophy consistent with nephronophthisis. Peritoneal dialysis
was required followed by renal transplantation at 6 years of age.
Compound heterozygous mutations (nonsense and missense) in
the RPGRIP1L gene were identified in this patient (table 1) and
his affected brother who required kidney transplantation but has
no clinical evidence of liver disease at 16 years of age (table 2).
COACH syndrome cohort
In our JSRD cohort of 251 families, 26 subjects (14 male, 12
female) in 23 families met criteria for COACH syndrome,
defined as JSRD plus clinically apparent liver disease (see
Methods). Most of the subjects were ascertained in the USA
(European, Asian, African, and Native American descent), with
one family each from Italy, the Netherlands, Germany, the UK,
and Turkey. No families were reported to be consanguineous.
The mean age of last ascertainment was 9 years with a range of
0e22 years. Developmental delay/intellectual disability, hypo-
tonia and abnormal eye movements were invariant features.
Assignment of CHF was made by histopathological means in 18
of 26 cases (63%). The DPM was reported in 1 of 24 subjects
(4%), with cirrhosis or chronic hepatitis observed in two of 24
subjects (8%). Pathological features of cholangitis were not seen
in any subjects. Portal hypertension developed in four subjects
(17%) and hypersplenism in one (4%) with portosystemic
shunting required in one (4%), and liver transplantation in two
(8%). No deaths thus far have resulted from liver disease.
Colobomata were present in 17 subjects (71%) and renal
disease was present in 10 subjects (42%): five with neph-
ronophthisis (or likely nephronophthisis) and six with macro-
cystic kidney disease. Chronic renal insufficiency or end stage
renal disease (ESRD) occurred in three (13%) and renal trans-
plantation was required in two (8%), with no deaths from renal
complications. Additional features included encephalocele (4%),
abnormal respiratory control (80%), hypoplasia/agenesis of the
corpus callosum (8%), ptosis (25%) and intestinal malrotation
(8%). No subjects had polydactyly or retinal dystrophy.
Mutation analysis
The identification of MKS3, CC2D2A and RPGRIP1L mutations
in JSRD patients with liver fibrosis prompted us to evaluate all of
our COACH patients for mutations in these three genes. In
subjects who did not have conclusive MKS3 mutations, we
sequenced CEP290, since CEP290mutations have been associated
with both MKS and JSRD. These probands (UW52, UW58,
UW59 and UW72) did not have mutations in CC2D2A,
RPGRIP1L, CEP290, AHI1 nor deletion of the NPHP1 gene. One
proband (UW66) lacked mutations in MKS3, CC2D2A,
RPGRIP1L, CEP290, AHI1 and deletion of the NPHP1 gene.
MKS3
Affected subjects in 16 pedigrees (70%) had twomutations in the
MKS3 gene, while one family carried two possible mutations (see
below), and single mutations were found in an additional three
subjects in two families (table 1). The 17 subjects with two
mutations had either: (1) two missense mutations (n¼ 8); or
combinations of (2) one missense and one nonsense mutation
(n¼ 4); (3) one missense and one splice site mutation (n¼ 4); or
(4) one nonsense mutation and one possible splice site mutation
(n¼ 1). The splice site mutation in UW05 (c.1674+3A>G)
results in the use of a cryptic splice site 124 nucleotides within
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intron 16, creating a stop codon one amino acid after exon 16. We
were not able to directly assess the functional significance of the
splice site changes in UW59 (intron 25, c.2661+5G>A) and
UW57 (intron 9, c.978+3A>G) because we do not have cell lines
from these subjects; however, the mutations greatly decrease the
predicted strength of the donor sites in multiple splice site
modelling programs (see Methods).
Several subjects did not have conclusive mutations in both
copies of the MKS3 gene. In UW58, the K99N change is not
a known polymorphism, is not seen in >192 control chromo-
somes, and is conserved throughout mammals, platypus and
opossum; however, it is predicted to be benign by PolyPhen.42
The splice site change did not alter the splicing of exon 22 in
a lymphoblastoid cell line, raising additional concern that loss of
MKS3 function is not the cause in this proband. In the two
probands with single mutations, we identified a frameshift
mutation that truncates the last 61 amino acids of the protein
(UW52) and a M252T change (UW72), previously reported in
three MKS pedigrees, two of which carried a second truncating
mutation and manifested polydactyly.31 33
To determine whether MKS3 mutations were more prevalent
in COACH subjects compared to JSRD subjects without liver
disease, we sequenced MKS3 in probands from our entire cohort
of JSRD families without liver disease, excluding 41 families with
causal mutations in other JSRD genes (n¼ 168). We identified
mutations in four subjects from two families for a prevalence of
w1% in JSRD families lacking evidence of CHF (table 2). Previ-
ously unreported changes in residue 82 (p.P82R and p.P82S) were
seen in both of these families in trans with p.M252T in UW85
and a frameshift p.T193Tfs14X in UW86. In our entire JSRD
cohort, regardless of the presence or absence of liver disease, 9%
(21/232) of families hadMKS3mutations. In contrast to the high
correlation between liver disease and MKS3 mutation status,
MKS3 mutations were identified in 16/30 (53%) families with
coloboma, irrespective of liver disease: 15/16 (94%) COACH
families with coloboma carried at least one MKS3 mutation,
while only 1/14 (7%) families with coloboma but lacking clini-
cally apparent liver disease carried at least one MKS3 mutation.
MKS3 mutations were distributed throughout the protein
(figure 3), with the majority of the missense mutations located in
the N-terminal extracellular domain. Of the 20 missense muta-
tions identified inMKS3 probands, nine were novel (P82R, P82S,
K99N, R172Q, M257V, R441C, P485S, Q841P, F942C). Although
Q376E is a unique substitution, Q376P has been reported
earlier.37 These novel missense mutations were predicted to be
either possibly or probably damaging by PolyPhen42 and were
excluded as rare polymorphisms based on testing at least 210
control chromosomes. When possible, familial segregation of
mutations (n¼ 7) to exclude in cis inheritance of a variant were
confirmed (table 1). Five missense mutations, M252T (n¼ 2),
L349S (n¼ 2), Y513C (n¼ 2), C615R (n¼ 2), and I833T (n¼ 4)
were recurrent within the cohort. The phenotype of subjects
with MKS3 mutations does not differ markedly from the
subjects without MKS3 mutations in our cohort.
CC2D2A and RPGRIP1L
The affected subjects in UW49 and UW67 had truncating
CC2D2A mutations in combination with missense mutations
(table 1). Discordance for liver disease between siblings was
observed in UW04, where a combination of missense and
nonsense mutations in RPGRIP1L was identified as being caus-
ative; however, only one sibling had a liver biopsy as part of his
evaluation before renal transplantation. The phenotype of these
subjects is indistinguishable from the subjects with MKS3
mutations; however, all three COACH subjects with CC2D2A
and RPGRIP1Lmutations manifested renal disease. In contrast to
MKS3, the prevalence of CC2D2A mutations was similar in the
COACH cohort (2/23e9%) and the entire JSRD cohort (17/
183e9%). Likewise, the prevalence of RPGRIP1L mutations was
similar in the two cohorts (1/23e4% vs 4/174e2%).
Phenotypic spectrum of COACH patients
A comprehensive review of the medical literature, using the
same criteria for COACH syndrome, revealed 43 patients with
COACH syndrome from 26 families, including 21 males, 13
females, three fetuses of unknown gender, and 13 sets of siblings
(table 3).1 3 22 26 39 47e61 Two terminated fetuses assigned
a Joubert syndrome diagnosis by Baala et al had cerebellar vermis
hypoplasia, enlarged microcystic kidneys and hepatic fibrosis
determined by autopsy.22 The mean age at last follow-up of
patients in the literature was 14.5 years (range 0e46 years) versus
8.9 years (range 0e22 years) for our cohort. MKS3 mutations
Table 2 Phenotype of Joubert syndrome related disorder (JSRD) subjects withMKS3 and RPGRIP1Lmutations lacking clinically apparent liver disease
Pedigree Mutations Amino acid Age/sex CNS Liver Col RD Renal Other
MKS3
UW85-1 c.245C>G p.P82R 26y/M MTS  +R   Transient ELE (valproate)
c.755T>C p.M252T
UW85-2 c.245C>G p.P82R 22y/M MTS  +R   Ptosis
c.755T>C p.M252T
UW85-3 c.245C>G p.P82R 19y/M MTS  +R   
c.755T>C p.M252T
UW86 c.579_80delAG p.T193Tfs14X 2y/F MTS     
c. 244C>T p.P82S
RPGRIP1L
UW04-4* c.2413C>T p.R805X 16y/M MTS    EK AB, ptosis
c.1975T>C p.S659P Bx(7y):NPH
Tx(7y)
See table 1 for key to abbreviations.
All UW subjects had developmental delay/mental retardation, hypotonia and/or ataxia, oculomotor apraxia.
Age refers to age at last contact in years (y), months (m) or weeks gestation (w).
Laterality of manifestations is stated as either; R, right; L, left; or bilateral unless otherwise stated.
Outcome details are italicised and appear in the lower portion of the cell.
*Brother with liver disease is listed in table 1.
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were reported in 19 subjects from 11 families, with all but two
subjects from one family having two mutations. Additionally,
RPGRIP1L mutations were reported in two subjects (only one
mutation was identified in one of the two subjects). Mutation
testing was not reported in the remaining 22 subjects in 16
families.
We compared the frequency of clinical findings/complications
in our cohort of COACH patients (this work) to all reported
COACH patients (literature) and all reported COACH patients,
with and without MKS3 mutations (table 4). Despite the
substantial ascertainment bias and differential reporting of clin-
ical features, this analysis gives some sense of the frequency of
complications seen in COACH syndrome. The results for the
literature as a whole are biased toward COACH syndrome caused
by MKS3 mutations, since Brancati et al39 describe their eight
families with MKS3 mutations and not the six families without
MKS3 mutations. Combining our COACH patients with MKS3
mutations with the similarly ascertained patients described by
Brancati et al39 provides estimates of features/complications in
this select group. Our cohort provides the only estimate of
complications in JSRD patients with MKS3 mutations inde-
pendent of liver disease status, since Brancati et al39 did not report
MKS3 mutation analysis in their JSRD patients without clini-
cally apparent liver disease.
The liver disease in our cohort encompassed multiple
outcomes ranging from asymptomatic elevation of liver
enzymes to organomegaly and portal hypertension and is
comparable to patients described in the literature. The renal
disease in patients with and without MKS3 mutations ranged
from prenatal onset MKS-like cystic renal dysplasia31 33 to an
infantile onset ARPKD-like presentation,62 to early childhood
onset cystic dysplasia,39 and to late childhood/adult onset
nephronophthisis.22 Severe liver and renal complications (death,
porto-systemic shunt, dialysis or transplantation) were some-
what more frequent in the literature, possibly due to the older
age at last ascertainment, preferential reporting of more severe
cases with renal disease,50 53 56 58 59 differences in medical prac-
tice, and/or the highly variable nature of disease progression.16
The frequency of coloboma (64% vs 71%), encephalocele (0% vs
7%), polydactyly (0% vs 5%), and ptosis (16% vs 25%) were
similar across groups.
DISCUSSION
Summary of main findings
We have identified the genetic bases of COACH syndrome (JSRD
with liver disease) in the largest cohort of such patients
published to date, finding mutations in all but one of 23 families.
Mutations in MKS3 account for the vast majority of COACH
subjects, while CC2D2A and RPGRIP1L mutations account for
a minority. By contrast, MKS3 mutations were uncommon in
JSRD subjects lacking clinically apparent liver disease. Further-
more, only 2/20 families (4/23 subjects) with JSRD due toMKS3
mutations did not have liver disease, confirming this highly
specific genotype-phenotype correlation. Brancati et al39
described a 57% prevalence of at least one MKS3 mutation in
their cohort of 14 similarly ascertained families, giving a preva-
lence of 73% in our combined cohorts which were ascertained in
a similar manner. Based on our observations, mutations inMKS3
are rarely seen in JSRD patients without liver disease; however,
the full phenotypic spectrum ofMKS3 related ciliopathy may be
even broader, given the report of a patient with a homozygous
MKS3 mutation but minimal neurological involvement.62
Although patients with liver involvement may be somewhat
over-represented in our cohort, MKS3mutations account for 9%
of our JSRD subjects irrespective of liver involvement, on par
with the other major JSRD genes AHI1, CC2D2A and CEP290.
The striking association of MKS3mutations with liver disease
in JSRD contrasts with the less clear-cut genotypeephenotype
Figure 3 MKS3 mutations in COACH and Meckel syndromes. MKS3 encodes a 995 amino acid predicted protein with a signal peptide (sig), cysteine
rich region, three transmembrane (TM) domains and a coiled-coil (CC) domain. Mutations identified in JSRD/COACH patients are listed above the protein
diagram while mutations found in MKS patients are listed below. Previously unreported mutations are indicated with an asterix (*) and mutations also
observed by Brancati et al39 are indicated with a plus sign (+).
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correlations observed for other JSRD genes that have hindered
selective gene testing. Among these correlations, retinal
dystrophy is seen in most subjects with AHI1 mutations,
many with CEP290 mutations and few with RPGRIP1L
mutations.17 19e21 29 63 64 Renal disease is seen in virtually all
subjects with NPHP1 deletions, many subjects with RPGRIP1L
andCEP290mutations, but very fewwith AHI1mutations.25 65e68
Other features may help distinguish patients with MKS3 muta-
tions, since we observed coloboma and renal disease in substantial
subsets of our subjects, while polydactyly and retinal disease were
absent. These findings have clear clinical implications for JSRD
patients with liver disease: MKS3 should be tested first, followed
by CC2D2A and possibly RPGRIP1L.
MKS3 mutations in JSRD versus MKS
The spectrum of MKS3 mutations differs between JSRD and
MKS subjects. We and others have identified single MKS3
mutations in both JSRD and MKS, consistent with the presence
of second non-coding mutations in MKS3 versus the possibility
of oligogenic inheritance seen in other ciliopathies such as
BardeteBiedl syndrome and nephronophthisis.69e72 Many
subjects with JSRD/COACH carry compound missense muta-
tions, while this has been reported in only one subject with
MKS.22 Both families with JSRD due toMKS3mutations, but no
clinically apparent liver disease, have mutations that alter the
proline at residue 82; however, the significance of this finding is
unclear and will need to be evaluated in additional patients. MKS
is typically caused by combinations of missense and truncating
mutations or homozygous splice site mutations.22 31 33 37 No
JSRD and MKS subjects have the same combination of muta-
tions and only two nonsense mutations (R208X, R451X) and
a single missense mutation (L349S) are shared between the
cohorts. These data suggest that MKS may be caused by more
severe loss of MKS3 function than JSRD.
COACH phenotypes
We report clinical features of all patients with COACH
syndrome in a cohort of JSRD patients ascertained only by brain
imaging findings, in contrast to case series in the literature that
ascertained patients specifically for brain, liver and sometimes
renal involvement. Brancati et al39 report a relatively large
number of families ascertained by brain imaging findings, but
only subjects with MKS3 mutations are described in detail. The
reported complications from portal hypertension with poten-
tially fatal variceal bleeding highlight the need for close moni-
toring of these patients.3 50 52 55 57 73 The presence of liver disease
associated with mutations in multiple JSRD genes (MKS3,
CC2D2A, RPGRIP1L and CEP290) raises the question of whether
subclinical liver involvement is present in many more subjects
with JSRD, and if present, whether subclinical disease ever
becomes clinically significant.
Pathological findings in the livers of the three subjects with
MKS3, CC2D2A and RPGRIP1Lmutations were compatible with
the variable changes seen in CHF, including an excess of bile duct
profiles and progressive portal fibrosis in the subject for whom
serial biopsies were available. Although cirrhosis/chronic hepa-
titis is not typical for CHF the cirrhosis reported in 2/40 post-
natal COACH subjects may be due to prior cholangitis, a known
complication of CHF, (described in 4/40 COACH patients) versus
misclassification of the clinical biopsy findings. The proposed
ciliary function for MKS3, CC2D2A and RPGRIP1L supports
a unified underlying pathophysiology for liver disease in JSRD
and MKS.
Coloboma is not an invariant feature of COACH patients
defined by the presence of the MTS and liver disease, and in this
regard diverges from the original specification of COACH
syndrome.1 Nonetheless, in our cohort, coloboma was associated
with liver disease (50% of the time) and MKS3 mutations (53%
of the time). These associations are also present in the cohort
described by Brancati et al.39 Therefore, monitoring for liver
disease andMKS3 testing are indicated in all JSRD subjects with
coloboma.
Nephronophthisis and larger, mixed size renal cystic disease
appear indistinguishable at the histopathological level,74
consistent with a renalMKS3 spectrum. Direct comparison with
the literature cohort is also problematic as juvenile neph-
ronophthisis manifests with renal failure at a mean age of 13
years,75 close to the mean age of the literature cohort, versus our
UW-MKS3 cohort mean (8.9 years). Overall, 12% of the
combined cohorts of comparably ascertained MKS3 cases had
chronic renal failure or ESRD, with one subject receiving a renal
transplant (3% prevalence). Due to the high risk of renal disease,
COACH syndrome patients should be closely monitored for renal
disease regardless of mutation status.
The prevalence of ptosis in our study is consistent with the
prior reports as well as brainstem abnormalities observed in
autopsies of JSRD subjects.4 46 The low prevalence of encepha-
locele in COACH patients contrasts with the 60e90% reported
in MKS patients.10e13 The surprising lack of polydactyly in
COACH syndrome may reflect the stronger association of poly-
dactyly withMKS1mutations (versusMKS3mutations) seen in
MKS.31 33
Conclusion
We have identified the genetic cause for the majority of JSRD
patients with liver involvement, also known as COACH
Table 4 Comparison of clinical features reported in COACH patients: our cohort versus all patients in the
literature versus COACH patients with and without known MKS3 mutations
This work Literature
Known MKS3
mutations
No known MKS3
mutations
Liver complications 21% (5/24) 40% (16/40) 22% (7/32) 47% (15/32)
Coloboma 71% (17/24) 64% (25/39) 66% (21/32) 68% (21/31)
Renal disease 46% (12/26) 77% (33/43) 39% (13/33) 88% (30/34)
Renal complications 8% (2/24) 22% (9/40) 12% (4/32) 22% (7/32)
Encephalocele 4% (1/26) 7% (3/42) 6% (2/33) 3% (1/33)
Ptosis 25% (6/24) 18% (7/40) 16% (5/32) 25% (8/32)
Polydactyly 0% (0/24) 5% (2/43) 3% (1/33) 3% (1/34)
Liver complications included porto-systemic shunt, transplantation and death, while renal complications included transplantation,
dialysis and death. The denominators differ in some cases because liver complications, coloboma, renal complications and ptosis
were not scored in all cases, particularly in fetuses.
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syndrome. Pre-symptomatic, gene based diagnosis of MKS3
mutations should make it possible to deliver improved medical
and surgical care for the liver and renal complications associated
with substantial morbidity and mortality. Assuming that our
JSRD cohort reflects JSRD in the population, patients with
known liver involvement should be tested first for MKS3
mutations, followed by CC2D2A and RPGRIP1L.
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